利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.028 秒)

    Nitrosated and nitrosylated prostaglandins, compositions and methods of use
    1.
    发明申请
    Nitrosated and nitrosylated prostaglandins, compositions and methods of use 失效
    亚硝化和亚硝酰化前列腺素，组合物和使用方法

    公开(公告)号：US20070112067A1

    公开(公告)日：2007-05-17

    申请号：US11641050

    申请日：2006-12-19

    申请人： David Garvey ,  Ricky Gaston ,  L. Letts ,  Inigo de Tejada ,  Sang Tam ,  Manuel Worcel

    发明人： David Garvey ,  Ricky Gaston ,  L. Letts ,  Inigo de Tejada ,  Sang Tam ,  Manuel Worcel

    IPC分类号： A61K31/21 ,  C07C203/02

    CPC分类号： A61K31/5575

    摘要： The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.

    摘要翻译： 本发明描述了新的亚硝化和/或亚硝基化的前列腺素，以及包含至少一种亚硝化和/或亚硝基化的前列腺素的新组合物，以及任选的至少一种捐赠，转移或释放一氧化氮的化合物，提高内源性内皮水平的放松 因子，刺激一氧化氮的内源性合成或是一氧化氮合酶的底物和/或至少一种血管活性剂。 本发明还提供了包含至少一种前列腺素和至少一种S-亚硝基硫醇化合物和任选的至少一种血管活性剂的新型组合物。 前列腺素优选为前列腺素E 1化合物，更优选前列地尔，S-亚硝基硫醇化合物优选为S-亚硝基谷胱甘肽。 本发明还提供用于治疗或预防男性和女性的性功能障碍的方法，用于增强男性和女性的性反应，以及用于治疗或预防脑血管疾病，心血管疾病，良性前列腺增生（BPH），青光眼，消化性溃疡或诱导 堕胎

    Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
    2.
    发明申请
    Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use 审中-公开
    硝基化和亚硝基化心血管化合物，组合物和使用方法

    公开(公告)号：US20070010571A1

    公开(公告)日：2007-01-11

    申请号：US10569077

    申请日：2004-08-20

    申请人： David Garvey ,  L. Letts ,  Manuel Worcel ,  Ricky Gaston

    发明人： David Garvey ,  L. Letts ,  Manuel Worcel ,  Ricky Gaston

    IPC分类号： A61K31/405 ,  A61K31/138 ,  C07D209/20

    CPC分类号： C07D493/04 ,  C07D407/04 ,  C07K5/06026

    摘要： The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at,least one cardiovascular compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; and (k) treating nephropathy. The nitrosated and/or nitrosylated cardiovascular compounds are preferably nitrosated and/or nitrosylated P-adrenergic antagonists, nitrosated and/or nitrosylated angiotensinconverting enzyme (ACE) inhibitors, nitrosated and/or nitrosylated anti-hyperlipidemic compounds, and nitrosated and/or nitrosylated antithrombotic and vasodilator compounds.

    摘要翻译： 本发明描述了新的亚硝化和/或亚硝基化的心血管化合物或其药学上可接受的盐，以及包含至少一种亚硝化和/或亚硝基化的心血管化合物和任选的至少一种一氧化氮供体和/或至少一种治疗剂的新组合物 。 本发明还提供了包含至少一种本发明的心血管化合物，其任选被亚硝化和/或亚硝基化的新组合物和试剂盒，以及任选的至少一种一氧化氮供体化合物和/或至少一种治疗剂。 本发明还提供了（a）治疗心血管疾病的方法; （b）治疗血管性疾病; （c）治疗糖尿病; （d）治疗由氧化应激引起的疾病; （e）治疗内皮功能障碍; （f）治疗由内皮功能障碍引起的疾病; （g）治疗肝硬化; （h）治疗先兆子痫; （j）治疗骨质疏松症; 和（k）治疗肾病。 亚硝化和/或亚硝基化的心血管化合物优选为亚硝化和/或亚硝化的P-肾上腺素能拮抗剂，亚硝化和/或亚硝化的血管紧张素转换酶（ACE）抑制剂，亚硝化和/或亚硝化的抗高脂血症化合物，以及亚硝化和/或亚硝化的抗血栓形成和/ 血管扩张剂化合物。

    Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
    4.
    发明申请
    Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use 审中-公开
    亚硝化和亚硝基化心血管化合物，组合物和使用方法

    公开(公告)号：US20070238740A1

    公开(公告)日：2007-10-11

    申请号：US10568819

    申请日：2004-08-20

    申请人： David Garvey ,  L. Letts ,  Manuel Worcel

    发明人： David Garvey ,  L. Letts ,  Manuel Worcel

    IPC分类号： A61K31/41 ,  A61K31/4164 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K31/519 ,  C07D233/42 ,  C07D233/54 ,  C07D239/22 ,  C07D257/04 ,  C07D401/10 ,  C07D403/10 ,  C07D471/04 ,  C07D487/04

    CPC分类号： C07D403/10 ,  C07C205/40 ,  C07D233/68 ,  C07D235/18 ,  C07D257/04 ,  C07D307/52 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/06 ,  C07D409/14 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04

    摘要： The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one cardiovascular compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; and (k) treating nephropathy. The nitrosated and/or nitrosylated cardiovascular compounds are preferably nitrosated and/or nitrosylated aldosterone antagonists, nitrosated and/or nitrosylated angiotensin II antagonists, nitrosated and/or nitrosylated calcium channel blockers, nitrosated and/or nitrosylated endothelin antagonists, nitrosated and/or nitrosylated hydralazine compounds, nitrosated and/or nitrosylated neutral endopeptidase inhibitors and nitrosated and/or nitrosylated renin inhibitors.

    摘要翻译： 本发明描述了新的亚硝化和/或亚硝基化的心血管化合物或其药学上可接受的盐，以及包含至少一种亚硝化和/或亚硝基化的心血管化合物和任选的至少一种一氧化氮供体和/或至少一种治疗剂的新组合物 。 本发明还提供了包含至少一种本发明的心血管化合物，其任选被亚硝化和/或亚硝基化的新组合物和试剂盒，以及任选的至少一种一氧化氮供体化合物和/或至少一种治疗剂。 本发明还提供了（a）治疗心血管疾病的方法; （b）治疗血管性疾病; （c）治疗糖尿病; （d）治疗由氧化应激引起的疾病; （e）治疗内皮功能障碍; （f）治疗由内皮功能障碍引起的疾病; （g）治疗肝硬化; （h）治疗先兆子痫; （j）治疗骨质疏松症; 和（k）治疗肾病。 亚硝化和/或亚硝基化的心血管化合物优选为亚硝化和/或亚硝基化的醛固酮拮抗剂，亚硝化和/或亚硝酰化的血管紧张素II拮抗剂，亚硝化和/或亚硝酰化的钙通道阻断剂，亚硝化和/或亚硝基化的内皮素拮抗剂，亚硝化和/ 化合物，亚硝化和/或亚硝基化的中性内肽酶抑制剂和亚硝化和/或亚硝基化的肾素抑制剂。

    Nitric oxide enhancing diuretic compounds, compositions and methods of use
    5.
    发明申请
    Nitric oxide enhancing diuretic compounds, compositions and methods of use 失效
    一氧化氮增强利尿剂，组合物和使用方法

    公开(公告)号：US20060189603A1

    公开(公告)日：2006-08-24

    申请号：US11360599

    申请日：2006-02-24

    申请人： David Garvey ,  L. Letts ,  Richard Earl ,  Maiko Ezawa ,  Xinqin Fang ,  Ricky Gaston ,  Subhash Khanapure ,  Chia-En Lin ,  Ramani Ranatunge ,  Cheri Stevenson ,  Shiow-Jyi Wey

    发明人： David Garvey ,  L. Letts ,  Richard Earl ,  Maiko Ezawa ,  Xinqin Fang ,  Ricky Gaston ,  Subhash Khanapure ,  Chia-En Lin ,  Ramani Ranatunge ,  Cheri Stevenson ,  Shiow-Jyi Wey

    IPC分类号： A61K31/549 ,  C07D417/02

    CPC分类号： C07D285/30 ,  C07D285/28 ,  C07D285/32 ,  C07D417/04 ,  C07D417/06 ,  C07D513/10

    摘要： The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

    摘要翻译： 本发明描述了包含至少一种一氧化氮增强利尿剂或其药学上可接受的盐，和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的新型组合物和试剂盒。 本发明还提供了（a）处理由过量水和/或电解质滞留导致的条件的方法; （二）治疗心血管疾病; （c）治疗血管性疾病; （d）治疗糖尿病; （e）治疗由氧化应激引起的疾病; （f）治疗内皮功能障碍; （g）治疗由内皮功能障碍引起的疾病; （h）治疗肝硬化; （j）治疗先兆子痫; （k）治疗骨质疏松症; （l）治疗肾病; （m）治疗外周血管疾病; （n）治疗门静脉高压; （o）治疗中枢神经系统疾病; （p）治疗代谢综合征; （q）治疗性功能障碍; 和（r）高脂血症。 一氧化氮增强利尿化合物包含通过一个或多个位点如碳，氧和/或氮通过不能水解的键或部分与利尿剂化合物连接的至少一个一氧化氮增强基团。

    Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
    6.
    发明申请
    Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效

    公开(公告)号：US20070004788A1

    公开(公告)日：2007-01-04

    申请号：US11518231

    申请日：2006-09-11

    申请人： David Garvey ,  L. Letts ,  Chia-En Lin ,  Tiansheng Wang

    发明人： David Garvey ,  L. Letts ,  Chia-En Lin ,  Tiansheng Wang

    IPC分类号： A61K31/426

    CPC分类号： C07D233/54 ,  C07D233/64 ,  C07D277/48 ,  C07D295/092 ,  C07D295/096

    摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

    NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE
    8.
    发明申请
    NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
    硝基脲泵抑制剂，组合物和使用方法

    公开(公告)号：US20070179150A1

    公开(公告)日：2007-08-02

    申请号：US11689568

    申请日：2007-03-22

    申请人： Xinqin Fang ,  David Garvey ,  L. Letts

    发明人： Xinqin Fang ,  David Garvey ,  L. Letts

    IPC分类号： A61K31/496 ,  A61K31/4745 ,  A61K31/4709 ,  C07D471/02 ,  C07D401/02 ,  C07D403/02

    CPC分类号： C07D401/12

    摘要： The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti-Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.

    摘要翻译： 本发明描述了新的亚硝化质子泵抑制剂化合物及其药学上可接受的盐，以及包含至少一种亚硝化质子泵抑制剂化合物和任选的至少一种捐赠，转移或释放一氧化氮的化合物，刺激内源性硝酸合成的新型组合物 氧化物，提高内源性内源性水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或至少一种治疗剂。 本发明还提供了包含至少一种亚硝化质子泵抑制剂化合物和至少一种捐赠，转移或释放一氧化氮的化合物的新型组合物，提高内源性内皮衍生的松弛因子水平，刺激一氧化氮的内源性合成或是底物 用于一氧化氮合酶和/或至少一种治疗剂。 本发明还提供了包含至少一种亚硝化质子泵抑制剂化合物和任选的至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。 本发明还提供了治疗胃肠道疾病的方法; 促进溃疡愈合; 减少溃疡复发; 改善胃保护性质，抗幽门螺旋杆菌性质或质子泵抑制剂的抗酸性; 降低或减少与使用非甾体抗炎化合物相关的胃肠道毒性; 治疗细菌感染和/或病毒感染。

    Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
    9.
    发明申请
    Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders 失效
    亚硝化和亚硝化化合物及其组合物及其用于治疗呼吸系统疾病的用途

    公开(公告)号：US20070155781A1

    公开(公告)日：2007-07-05

    申请号：US11604677

    申请日：2006-11-28

    申请人： David Garvey ,  L. Letts ,  H. Renfroe ,  Stewart Richardson

    发明人： David Garvey ,  L. Letts ,  H. Renfroe ,  Stewart Richardson

    IPC分类号： A61K31/46 ,  C07D451/02

    CPC分类号： C07D451/06 ,  C07C313/36 ,  C07D311/22 ,  C07D451/10 ,  C07D471/04 ,  C07J5/00 ,  C07J7/00 ,  C07J31/00 ,  C07J71/00 ,  C07J71/0031

    摘要： Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO+) or nitroxyl (NO−), or as the neutral species, nitric oxide (NO.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

    摘要翻译： 公开的是（i）直接或间接连接到NO或NO 2基团或基团上的基团的类固醇，β-激动剂，抗胆碱能药，肥大细胞稳定剂和磷酸二酯酶（PDE）抑制剂的化合物 其在体内刺激NO或EDRF的内源性产生; （ii）类固醇，β-激动剂，抗胆碱能药物，肥大细胞稳定剂和PDE抑制剂的组合物，其可任选地被至少一个NO或NO 2个部分取代，或刺激内源性产生NO 或EDRF，以及作为带电物质，即亚硝酸盐（硝酸）或硝酰基（NO +）的一氧化氮，或NOX + 作为中性物种，一氧化氮（NO））或者在体内刺激NO或EDRF的内源性产生; 和（iii）用于预防和/或治疗呼吸系统疾病。

    Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
    10.
    发明申请
    Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use 失效
    亚硝化和/或亚硝基化的环氧合酶-2选择性抑制剂，组合物和使用方法

    公开(公告)号：US20070179195A1

    公开(公告)日：2007-08-02

    申请号：US11730886

    申请日：2007-04-04

    申请人： L. Letts ,  David Garvey

    发明人： L. Letts ,  David Garvey

    IPC分类号： A61K31/21 ,  C07C229/38

    CPC分类号： C07D295/185 ,  A61K45/06 ,  C07C229/42 ,  C07C317/18 ,  C07C323/12 ,  C07D493/04

    摘要： The invention provides novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions and kits comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

    摘要翻译： 本发明提供新的亚硝化和/或亚硝基化的环氧合酶2（COX-2）选择性抑制剂和包含至少一种亚硝化和/或亚硝基化的环氧合酶2（COX-2）选择性抑制剂的新组合物和试剂盒，以及任选的至少一种化合物 捐赠，转移或释放一氧化氮，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或任选的至少一种治疗剂。 本发明还提供了治疗炎症，疼痛和发烧的方法; 用于治疗和/或改善COX-2选择性抑制剂的胃肠性质; 促进伤口愈合; 用于治疗和/或预防肾和/或呼吸毒性; 用于治疗和/或预防由环氧合酶-2水平升高引起的其他疾病; 并用于改善COX-2选择性抑制剂的心血管外形。